Use of kidneys from hepatitis C seropositive donors shortens waitlist time but does not alter one-yr outcome

Clinical Transplantation

Volumn 17, Issue 5, 2003, Pages 433-437

  Woodside, Kenneth J ^a   Ishihara, Kanae ^a   Theisen, James E ^a   Early, Marilyn G ^a   Covert, Lesa G ^a   Hunter, Glenn C ^a   Gugliuzza, Kristene K ^a   Daller, John A ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Donor selection; Graft survival; Hepatitis C; Liver function; Marginal organ donors; Patient survival; Renal transplantation; Waitlist time

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHIMERIC ANTIBODY; CREATININE; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; THYMOCYTE ANTIBODY;

ACUTE DISEASE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CADAVER DONOR; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GRAFT SURVIVAL; HEPATITIS C; HUMAN; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; KIDNEY TUBULE NECROSIS; LIVER FUNCTION TEST; LIVER LEVEL; MALE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; FEMALE; HEPATITIS C ANTIBODIES; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TISSUE DONORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 0141990519     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2003.00067.x     Document Type: Article

References (13)

1. Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation 2001: 72: 241.
2. Lee WC, Shu KH, Cheng CH et al. Long-term impact of hepatitis B, C virus infection on renal transplantation. Am J Nephrol 2001: 21: 300.
3. Mandal AK, Kraus ES, Samaniego, M et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transplant 2000: 14: 391.
4. Morales JM, Campistol JM. Transplantation in the patient with hepatitis C. J Am Soc Nephrol 2000: 11: 1343.
5. Domínguez-Gil B, Esforzado N, Muñoz MA et al. Trasplante renal utilizando riñones de donantes con serología positiva para el virus de la hepatitis C. Nefrología 2001: 21: S119.
6. Marelli D, Bresson J, Laks H et al. Hepatitis C-positive donors in heart transplantation. Am J Transplant 2002: 2: 443.
7. Kiberd BA. Should hepatitis C-infected kidneys be transplanted in the United States? Transplantation 1994: 57: 1068.
8. Farci P, Alter HJ, Govindarajan S et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992: 258: 135.
9. Widell A, Mansson S, Persson NH et al. Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney. Transplantation 1995: 60: 642.
10. Notov SN, Lau JYN, Turhazer R et al. Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. Kidney Int 1999: 56: 700.
11. Ali MK, Light JA, Barhyte DY et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV + recipients in renal transplantation. Transplantation 1998: 66: 1694.
12. Morales JM, Capistol JM, Castellano G et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplant anti-HCV. Kidney Int 1995: 47: 236.
13. Mange KC, Joe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 2001: 344: 726.